CycB/CCNB1 Cancer Research Results

CycB/CCNB1, Cyclin B: Click to Expand ⟱
Source:
Type:
When cyclin B levels are elevated, cells can enter M phase prematurely and strict control over cell division is lost, which is favorable for cancer development.
Cyclin B is a regulatory protein that plays a crucial role in cell cycle progression, particularly in the transition from the G2 phase to mitosis. Its expression levels can significantly impact cancer progression and patient prognosis.
Cyclin B expression is often elevated in various cancers and is generally associated with poor prognosis.
Cyclin B levels:
-Accumulate during S and G2
-Peak at mitotic entry
-Are rapidly destroyed at metaphase–anaphase transition via the APC/C ubiquitin ligase


Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
3160- Ash,    Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal
- Review, Var, NA
TumCCA↑, H3↑, P21↑, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDC2↓, CHK1↓, Chk2↓, p38↑, MAPK↑, E6↓, E7↓, P53↑, Akt↓, FOXO3↑, ROS↑, γH2AX↑, MMP↓, mitResp↓, eff↑, TumCD↑, Mcl-1↓, ER Stress↑, ATF4↑, ATF3↑, CHOP↑, NOTCH↓, NF-kB↓, Bcl-2↓, STAT3↓, CDK1↓, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, Cyt‑c↑, eff↑, CDK4↓, p‑RB1↓, PARP↑, cl‑Casp3↑, cl‑Casp9↑, NRF2↑, ER-α36↓, LDHA↓, lipid-P↑, AP-1↓, COX2↓, RenoP↑, PDGFR-BB↓, SIRT3↑, MMP2↓, MMP9↓, NADPH↑, NQO1↑, GSR↑, HO-1↑, *SOD2↑, *Prx↑, *Casp3?, eff↑, Snail↓, Slug↓, Vim↓, CSCs↓, HEY1↓, MMPs↓, VEGF↓, uPA↓, *toxicity↓, CDK2↓, CDK4↓, HSP90↓,
5362- AV,    Anti-cancer effects of aloe-emodin: a systematic review
- Review, Var, NA
AntiCan↑, eff↝, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, TumCD↑, MMP↓, ROS↑, Apoptosis↑, CDK1↓, CycB/CCNB1↓, Bcl-2↓, PCNA↓, ATP↓, ER Stress↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, MMP2↓, Ca+2↑, DNAdam↑, Akt↓, PKCδ↓, mTORC2↓, GSH↓, ChemoSen↑,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
4514- MAG,    Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, TumMeta↓, angioG↓, NF-kB↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, BioAv↓, *antiOx↑, *Inflam↓, *AntiAg↑, ChemoSen↑, cycD1/CCND1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p27↑, P21↑, P53↑, PTEN↓, XIAP↓, Mcl-1↓, Casp3↑, Casp9↑, MMP9↑,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX↑, P21↑, p27↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
1664- PBG,    Anticancer Activity of Propolis and Its Compounds
- Review, Var, NA
Apoptosis↑, TumCMig↓, TumCCA↑, TumCP↓, angioG↓, P21↑, p27↑, CDK1↓, p‑CDK1↓, cycA1/CCNA1↓, CycB/CCNB1↓, P70S6K↓, CLDN2↓, HK2↓, PFK↓, PKM2↓, LDHA↓, TLR4↓, H3↓, α-tubulin↓, ROS↑, Akt↓, GSK‐3β↓, FOXO3↓, NF-kB↓, cycD1/CCND1↓, MMP↓, ROS↑, i-Ca+2↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, BAX↑, PUMA↑, ROS↑, MMP↓, Cyt‑c↑, cl‑Casp8↑, cl‑Casp8↑, cl‑Casp3↑, cl‑PARP↑, eff↑, eff↑, RadioS↑, ChemoSen↑, eff↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1/CCNA1↓, CycB/CCNB1↓, CDK2↓, P21↑, p27↑, hTERT/TERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
3256- PBG,    Mechanisms of Apoptosis and Cell Cycle Arrest Induced by Propolis in Cancer Therapy
- Review, Var, NA
TumCCA↑, CDK2↓, CDK4↓, cycA1/CCNA1↓, CycB/CCNB1↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
3354- QC,    Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine
- Review, Var, NA
*ROS↓, *IronCh↓, *lipid-P↓, *GSH↑, *NRF2↑, TumCCA↑, ER Stress↑, P53↑, CDK2↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, cycD1/CCND1↓, PCNA↓, P21↑, p27↑, PI3K↓, Akt↓, mTOR↓, STAT3↓, cFLIP↓, cMyc↓, survivin↓, DR5↓, *Inflam↓, *IL6↓, *IL8↓, COX2↓, 5LO↓, *cardioP↑, *FASN↓, *AntiAg↑, *MDA↓,
3343- QC,    Quercetin, a Flavonoid with Great Pharmacological Capacity
- Review, Var, NA - Review, AD, NA - Review, Arthritis, NA
*antiOx↑, *ROS↓, *angioG↓, *Inflam↓, *BioAv↓, *Half-Life↑, *GSH↑, *SOD↑, *Catalase↑, *Nrf1↑, *BP↓, *cardioP↑, *IL10↓, *TNF-α↓, *Aβ↓, *GSK‐3β↓, *tau↓, *neuroP↑, *Pain↓, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL17↓, *MCP1↓, PKCδ↓, ERK↓, BAX↓, cMyc↓, KRAS↓, ROS↓, selectivity↑, tumCV↓, Apoptosis↑, TumCCA↑, eff↑, P-gp↓, eff↑, eff↑, eff↑, eff↑, CycB/CCNB1↓, CDK1↓, CDK4↓, CDK2↓, TOP2↓, Cyt‑c↑, cl‑PARP↑, MMP↓, HSP70/HSPA5↓, HSP90↓, MDM2↓, RAS↓, eff↑,
1726- SFN,    Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential
- Review, Var, NA
Dose↝, eff↝, IL1β↓, IL6↓, IL12↓, TNF-α↓, COX2↓, CXCR4↓, MPO↓, HSP70/HSPA5↓, HSP90↓, VCAM-1↓, IKKα↓, NF-kB↓, HO-1↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, CHOP↑, survivin↓, XIAP↓, p38↑, Fas↑, PUMA↑, VEGF↓, Hif1a↓, Twist↓, Zeb1↓, Vim↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Snail↓, CD44↓, cycD1/CCND1↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK4↓, CDK6↓, p50↓, P53↑, P21↑, GSH↑, SOD↑, GSTs↑, mTOR↓, Akt↓, PI3K↓, β-catenin/ZEB1↓, IGF-1↓, cMyc↓, CSCs↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3289- SIL,    Silymarin: a promising modulator of apoptosis and survival signaling in cancer
- Review, Var, NA
*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, FOXM1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB/CCNB1↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,

Showing Research Papers: 1 to 19 of 19

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 19

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

antiOx↓, 1,   ATF3↑, 1,   Catalase↓, 1,   GSH↓, 3,   GSH↑, 1,   GSR↑, 1,   GSTs↑, 1,   HO-1↓, 1,   HO-1↑, 3,   lipid-P↓, 2,   lipid-P↑, 3,   MDA↑, 1,   MPO↓, 1,   NQO1↑, 2,   NRF2↓, 3,   NRF2↑, 3,   ROS↓, 4,   ROS↑, 16,   ROS⇅, 1,   SIRT3↑, 1,   SOD↓, 1,   SOD↑, 2,   SOD1↑, 1,   SOD2↑, 1,   Trx1↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics

ADP:ATP↑, 1,   ATP↓, 1,   mt-ATP↓, 1,   CDC2↓, 3,   CDC25↓, 3,   mitResp↓, 1,   MMP↓, 7,   Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis

AMPK↑, 1,   CAIX↑, 1,   cMyc↓, 7,   p‑cMyc↑, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   HK2↓, 3,   lactateProd↓, 1,   LDHA↓, 2,   NADPH↑, 1,   PDK1↓, 1,   PDK3↑, 1,   PFK↓, 1,   PKM2↓, 1,   Warburg↓, 1,  

Cell Death

Akt↓, 11,   Akt↑, 1,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 8,   BAX↓, 1,   BAX↑, 8,   Bcl-2↓, 8,   Bcl-2↑, 1,   Bcl-xL↓, 2,   BIM↑, 1,   Casp↑, 1,   Casp12↑, 1,   Casp3↓, 2,   Casp3↑, 8,   cl‑Casp3↑, 4,   Casp7↑, 2,   Casp8↑, 5,   cl‑Casp8↑, 3,   pro‑Casp8↑, 1,   Casp9↑, 9,   cl‑Casp9↑, 3,   proCasp9↓, 1,   cFLIP↓, 1,   Chk2↓, 1,   Cyt‑c↑, 7,   Diablo↑, 1,   DR5↓, 1,   DR5↑, 3,   FADD↑, 1,   Fas↑, 4,   FasL↑, 2,   HEY1↓, 1,   hTERT/TERT↓, 3,   IAP1↓, 1,   iNOS↓, 1,   JNK↓, 1,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↓, 2,   MAPK↑, 3,   Mcl-1↓, 4,   MDM2↓, 6,   NICD↓, 1,   p27↑, 6,   p38↑, 3,   p‑p38↓, 1,   PUMA↑, 2,   survivin↓, 8,   Telomerase↓, 1,   TumCD↑, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction

HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 2,  

Transcription & Epigenetics

H3↓, 1,   H3↑, 1,   other↓, 1,   tumCV↓, 2,  

Protein Folding & ER Stress

CHOP↑, 3,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 6,   GRP78/BiP↑, 2,   HSP70/HSPA5↓, 2,   HSP90↓, 3,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes

Beclin-1↑, 1,   BNIP3↑, 1,   LC3B-II↑, 1,   LC3II↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair

ATM↑, 1,   CHK1↓, 2,   DNAdam↑, 4,   DNArepair↑, 1,   P53↑, 11,   PARP↑, 1,   cl‑PARP↑, 5,   PCNA↓, 6,   γH2AX↑, 1,  

Cell Cycle & Senescence

CDK1↓, 7,   p‑CDK1↓, 1,   CDK2↓, 12,   CDK4↓, 10,   cycA1/CCNA1↓, 6,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 19,   cycD1/CCND1↓, 9,   cycE/CCNE↓, 5,   E2Fs↓, 1,   P21↑, 11,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 1,   TumCCA↑, 14,  

Proliferation, Differentiation & Cell State

CD44↓, 1,   cFos↓, 1,   cMET↓, 1,   CSCs↓, 3,   EMT↓, 6,   EMT↑, 1,   ERK↓, 5,   p‑ERK↓, 2,   FOXM1↓, 1,   FOXO3↓, 1,   FOXO3↑, 1,   p‑FOXO3↓, 1,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 1,   IGF-1↓, 1,   IGF-1R↓, 1,   mTOR↓, 6,   p‑mTOR↓, 1,   mTORC2↓, 1,   Nanog↓, 1,   NOTCH↓, 2,   NOTCH1↓, 1,   NOTCH1↑, 1,   OCT4↓, 1,   P70S6K↓, 1,   p‑P70S6K↓, 1,   PI3K↓, 8,   PTEN↓, 1,   PTEN↑, 1,   RAS↓, 3,   SOX2↓, 1,   STAT3↓, 8,   p‑STAT3↓, 1,   TAZ↓, 1,   TOP1↓, 1,   TOP2↓, 3,   TumCG↓, 2,   TumCG↑, 1,   Wnt↓, 2,  

Migration

5LO↓, 1,   AEG1↓, 1,   AP-1↓, 3,   Ca+2↑, 2,   i-Ca+2↑, 1,   Cdc42↑, 1,   CLDN2↓, 1,   E-cadherin↑, 7,   ER-α36↓, 1,   FAK↓, 2,   p‑FAK↓, 2,   Ki-67↓, 2,   KRAS↓, 1,   MMP1↓, 1,   MMP13↓, 2,   MMP2↓, 9,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 9,   MMP9↑, 2,   MMPs↓, 2,   N-cadherin↓, 6,   PKCδ↓, 3,   Rho↓, 2,   ROCK1↓, 2,   Slug↓, 2,   Snail↓, 4,   TGF-β↓, 2,   TIMP1↑, 1,   TIMP2↑, 2,   Treg lymp↓, 1,   TumCI↓, 3,   TumCMig↓, 3,   TumCP↓, 9,   TumMeta↓, 6,   TumMeta↑, 1,   Twist↓, 3,   uPA↓, 4,   VCAM-1↓, 1,   Vim↓, 6,   Zeb1↓, 1,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature

angioG↓, 9,   ATF4↑, 2,   EGFR↓, 1,   p‑EGFR↓, 1,   Hif1a↓, 6,   LOX1↓, 1,   NO↓, 1,   NO↑, 1,   PDGFR-BB↓, 1,   VEGF↓, 10,   VEGFR2↓, 2,  

Barriers & Transport

BBB↑, 1,   GLUT1↓, 2,   GLUT1↑, 1,   GLUT3↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling

CD4+↓, 1,   CD4+↑, 1,   COX2↓, 10,   COX2↑, 1,   CXCR4↓, 3,   FOXP3↓, 1,   IFN-γ↓, 1,   Igs↑, 1,   IKKα↓, 2,   IL1↓, 2,   IL12↓, 1,   IL1β↓, 3,   IL2↑, 1,   IL6↓, 6,   IL8↓, 4,   Inflam↓, 2,   JAK1↓, 1,   JAK2↓, 1,   MCP1↓, 1,   NF-kB↓, 13,   p‑NF-kB↑, 1,   NK cell↑, 2,   p50↓, 1,   PD-L1↓, 1,   PGE2↓, 2,   T-Cell↑, 1,   Th1 response↑, 1,   TLR4↓, 1,   TNF-α↓, 4,   TNF-α↑, 1,  

Hormonal & Nuclear Receptors

AR↓, 2,   CDK6↓, 2,   ER(estro)↓, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 5,   BioAv↑, 3,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 10,   Dose?, 1,   Dose↝, 1,   Dose∅, 1,   eff↓, 2,   eff↑, 21,   eff↝, 2,   Half-Life↓, 2,   MDR1↓, 1,   RadioS↑, 5,   selectivity↑, 3,  

Clinical Biomarkers

AR↓, 2,   E6↓, 1,   E7↓, 1,   EGFR↓, 1,   p‑EGFR↓, 1,   FOXM1↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 3,   IL6↓, 6,   Ki-67↓, 2,   KRAS↓, 1,   PD-L1↓, 1,  

Functional Outcomes

AntiCan↑, 5,   AntiTum↑, 1,   cardioP↑, 2,   chemoP↑, 2,   ChemoSideEff↓, 1,   OS↑, 1,   radioP↑, 2,   RenoP↑, 2,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 322

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 7,   Catalase↑, 5,   GPx↑, 3,   GSH↑, 5,   GSR↑, 1,   GSTs↑, 2,   HO-1↑, 1,   Keap1↓, 1,   lipid-P↓, 4,   MDA↓, 3,   MPO↓, 1,   Nrf1↑, 1,   NRF2↑, 4,   Prx↑, 1,   ROS↓, 9,   SOD↑, 5,   SOD2↑, 1,   TBARS↓, 1,  

Metal & Cofactor Biology

IronCh↓, 1,   IronCh↑, 1,  

Mitochondria & Bioenergetics

MMP↑, 1,  

Core Metabolism/Glycolysis

ALAT↓, 1,   FASN↓, 1,   H2S↑, 1,   LDH↓, 2,  

Cell Death

Akt↓, 1,   Casp3?, 1,   iNOS↓, 1,  

Transcription & Epigenetics

other↑, 1,  

Proliferation, Differentiation & Cell State

GSK‐3β↓, 1,   PI3K↓, 1,  

Migration

AntiAg↑, 2,  

Angiogenesis & Vasculature

angioG↓, 1,   NO↓, 2,  

Barriers & Transport

BBB↑, 2,  

Immune & Inflammatory Signaling

COX2↓, 2,   IL10↓, 1,   IL17↓, 1,   IL1β↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 5,   MCP1↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission

AChE↓, 1,   tau↓, 1,  

Protein Aggregation

Aβ↓, 2,  

Drug Metabolism & Resistance

BioAv↓, 5,   BioAv↑, 1,   BioAv↝, 1,   eff↑, 1,   Half-Life↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers

ALAT↓, 1,   AST↓, 1,   BP↓, 2,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 2,   LDH↓, 2,  

Functional Outcomes

cardioP↑, 3,   cognitive↑, 1,   hepatoP↑, 3,   memory↑, 1,   neuroP↑, 5,   Pain↓, 1,   toxicity↓, 2,  
Total Targets: 69

Scientific Paper Hit Count for: CycB/CCNB1, Cyclin B
4 Propolis -bee glue
2 Luteolin
2 Quercetin
2 Silymarin (Milk Thistle) silibinin
1 Allicin (mainly Garlic)
1 Artemisinin
1 Ashwagandha(Withaferin A)
1 Aloe anthraquinones
1 Berberine
1 Chrysin
1 Magnolol
1 Melatonin
1 Piperlongumine
1 Sulforaphane (mainly Broccoli)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:379  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page